All In Biotech

Drug Trial Radar · NCT06413537

Study of SPG601 in Adult Men With Fragile X Syndrome

A Phase 2a, Randomized, Double-Blinded, Study Evaluating the Neurophysiologic vs Clinical Effects of Single-Dose SPG601 and Placebo in Adult Men With Fragile X Syndrome

Last checked: Nov 19, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Jul 5, 2024

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
SpinogenixIndustry
Sponsor type
Industry
Collaborators
Avance Clinical Pty Ltd.
First posted
May 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.

Conditions

  • Fragile X Syndrome

Interventions

  • SPG601Drug

    synthetic small molecule

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Global Impressions Improvement Scale as Determined by the Treating ClinicianTime frame: 15 days
  2. Clinical Global Impressions Improvement Scale as Determined by the CaregiverTime frame: 15 days
  3. Visual Analog Scale as Determined by the Patient CaregiverTime frame: 15 days
  4. Change in Auditory Response to Chirp StimulusTime frame: 15 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.